Evaluation and Management of Seasonal Influenza in the Emergency Department

Emergency Medicine Clinics of North America

Volumn 30, Issue 2, 2012, Pages 271-305

  Afilalo, Marc ^a   Stern, Errol ^a   Oughton, Matthew ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Emergency department; Influenza; Seasonal

Indexed keywords

AMANTADINE; ANTIHISTAMINIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; OSELTAMIVIR; PROBENECID; RIMANTADINE; VIRUS ANTIGEN; VIRUS HEMAGGLUTININ; VIRUS RNA; VIRUS SIALIDASE; ZANAMIVIR;

BLOOD ANALYSIS; BRONCHOSPASM; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL EVALUATION; CLINICAL FEATURE; COUGHING; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EXCRETION; DRUG METABOLISM; DYSPNEA; EARLY DIAGNOSIS; EARLY INTERVENTION; EMERGENCY WARD; EPIDEMIC; FEVER; FLUORESCENT ANTIBODY TECHNIQUE; GASTROINTESTINAL DISEASE; GUILLAIN BARRE SYNDROME; HAND WASHING; HEADACHE; HEART DEATH; HOSPITAL HYGIENE; HOSPITALIZATION; HUMAN; IMMUNOFLUORESCENCE MICROSCOPY; INFECTION CONTROL; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INFLUENZA VIRUS C; LABORATORY TEST; MALAISE; MORBIDITY; MORTALITY; MYALGIA; MYELITIS; MYOCARDITIS; NOSE SMEAR; PATHOGENESIS; PATIENT CARE; POINT OF CARE TESTING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTECTIVE CLOTHING; RECOMMENDED DRUG DOSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; REYE SYNDROME; RISK ASSESSMENT; RNA ANALYSIS; SEASONAL INFLUENZA; SENSITIVITY AND SPECIFICITY; SPUTUM CULTURE; THORAX PAIN; THROAT CULTURE; TOXIC SHOCK SYNDROME; VIRUS CELL INTERACTION; VIRUS CULTURE; VIRUS ENCEPHALITIS; VIRUS IDENTIFICATION; VIRUS PNEUMONIA; VIRUS REPLICATION; VIRUS SHEDDING;

EID: 84859511821     PISSN: 07338627     EISSN: 07338627     Source Type: Journal    
DOI: 10.1016/j.emc.2011.10.011     Document Type: Review

References (95)

1. Simonsen L., Clarke M.J., Williamson G.D., et al. The impact of influenza epidemics on mortality: introducing a severity index. Am J Public Health 1997, 87(12):1944-1950.
2. Simonsen L., Clarke M.J., Schonberger L.B., et al. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J Infect Dis 1998, 178(1):53-60.
3. Thompson W.W., Shay D.K., Weintraub E., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289(2):179-186.
4. World Health Organization. Influenza. Available at: Accessed September 30, 2011. http://www.who.int/mediacentre/factsheets/2003/fs211/en/.htm.
5. Centers for Disease Control and Prevention. Key facts about the flu. Available at: Accessed September 30, 2011. http://www.cdc.gov/flu/keyfacts.htm.
6. Molinari N.M., Ortega-Sanchez I.R., Messonnier M.L., et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007, 25(27):5086-5096.
7. Neuzil K.M., Reed G.W., Mitchel E.F., et al. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA 1999, 281(10):901-907.
8. Canadian Consensus Conference on Influenza. Can Commun Dis Rep 1993, 19(17):136-142. 145-7.
9. Nichol K.L., Margolis K.L., Wuorenma J., et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994, 331:778-784.
10. Centers for Disease Control and Prevention Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2006. MMWR Recomm Rep 2006, 55(RR10):1-42.
11. Dowdle W.R., Coleman M.T., Gregg M.B. Natural history of influenza type A in the United States, 1957-1972. Prog Med Virol 1974, 17:91-135.
12. Ng T.P., Pwee K.H., Niti M., et al. Influenza in Singapore: assessing the burden of illness in the community. Ann Acad Med Singapore 2002, 31:182-188.
13. Monto A.S. Epidemiology of influenza. Vaccine 2008, 26(Suppl 4):D45-D48.
14. Glezen W.P., Couch R.B. Interpandemic influenza in the Houston area, 1974-76. N Engl J Med 1978, 298(11):587-592.
15. Dolin Raphael Epidemiology of influenza 2010, UpToDate, Available at:, Accessed September 30, 2011. http://www.uptodate.com/contents/epidemiology-ofinfluenza?source=search_result&search=EpidemiologyofInfluenza&selectedTitle=1%7E150.
16. Pons M.W. Isolation of influenza virus ribonucleoprotein from infected cells. Demonstration of the presence of negative-stranded RNA in viral RNP. Virology 1971, 46(1):149-160.
17. Beigel J.H. Influenza. Crit Care Med 2008, 36(9):2660-2666.
18. Homma M., Ohyama S., Katagiri S. Age distribution of the antibody to type C influenza virus. Microbiol Immunol 1982, 26:639-642.
19. Matsuzaki Y., Katsushima N., Nagai Y. Clinical features of influenza C virus infection in children. J Infect Dis 2006, 193(9):1229-1235.
20. Springer G.F., Schwick H.G., Fletcher M.A. The relationship of the influenza virus inhibitory activity of glycoproteins to their molecular size and sialic acid content. Proc Natl Acad Sci U S A 1969, 64:634-641.
21. Suzuki Y., Ito T., Suzuki T., et al. Sialic acid species as a determinant of the host range of influenza A viruses. J Virol 2000, 74:11825-11831.
22. Gottschalk A. The influenza virus neuraminidase. Nature 1958, 181:377-378.
23. Adachi M., Matsukura S., Tokunaga H., et al. Expression of cytokines on human bronchial epithelial cells induced by influenza virus A. Int Arch Allergy Immunol 1997, 113:307-311.
24. Ottolini M.G., Blanco J.C.G., Eichelberger M.C., et al. The cotton rat provides a useful small animal model for the study of influenza virus pathogenesis. J Gen Virol 2005, 86:2823-2830.
25. Couch R.B., Douglas R.G., Fedson D.S., et al. Correlated studies of a recombinant influenza-virus vaccine. III. Protection against experimental influenza in man. J Infect Dis 1971, 124(5):473-480.
26. Jordan W.S., Badger G.F., Dingle J.H. A study of illness in a group of Cleveland families. XVI. The epidemiology of influenza 1948-1953. Am J Hyg 1958, 68:169-189.
27. Ison M.G., Gnann J.W., Nagy-Agren S., et al. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther 2003, 8:183-190.
28. Treanor J.J., Hayden F.G., Vrooman P.S., et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 2000, 283(8):1016-1024.
29. Whitley R.J., Hayden F.G., Reisinger K.S., et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001, 20(2):127-133.
30. Sato M., Hosoya M., Kato K., et al. Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors. Pediatr Infect Dis J 2005, 24(10):931-932.
31. Leekha S., Zitterkopf N.L., Espy M.J., et al. Duration of influenza A virus shedding in hospitalized patients and implications for infection control. Infect Control Hosp Epidemiol 2007, 28(9):1071-1076.
32. Lee N., Chan P.K., Hui D.S., et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009, 200(4):492-500.
33. Klimov A., Rocha E., Hayden F.G., et al. Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. J Infect Dis 1995, 172(5):1352-1355.
34. Englund J.A., Champlin R.E., Wyde P.R., et al. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis 1998, 26(6):1418-1424.
35. Boivin G., Goyette N., Bernatchez H. Prolonged excretion of amantadine-resistant influenza A virus quasi species after cessation of antiviral therapy in an immunocompromised patient. Clin Infect Dis 2002, 34(5):e23-e25.
36. Nichols W.G., Guthrie K.A., Corey L., et al. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 2004, 39(9):1300-1306.
37. Weinstock D.M., Gubareva L.V., Zuccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N Engl J Med 2003, 348(9):867-868.
38. Kondo S., Abe K. The effects of influenza virus infection on FEV1 in asthmatic children. The time-course study. Chest 1991, 100(5):1235-1238.
39. Smith C.B., Kanner R.E., Goldern C.A., et al. Effect of viral infections on pulmonary function in patients with chronic obstructive pulmonary diseases. J Infect Dis 1980, 141(3):271-280.
40. Louria D.B., Blumenfeld H.L., Ellis J.T., et al. Studies on influenza in the pandemic of 1957-1958. II. Pulmonary complications of influenza. J Clin Invest 1959, 38:213-265.
41. Monto A.S., Gravenstein S., Elliott M., et al. Clinical signs and symptoms predicting influenza infection. Arch Intern Med 2000, 160(21):3243-3247.
42. Call S.A., Vollenweider M.A., Hornung C.A., et al. Does this patient have influenza?. JAMA 2005, 293(8):987-997.
43. Chiu S.S., Tse C.Y., Lau Y.L., et al. Influenza A infection is an important cause of febrile seizures. Pediatrics 2001, 108(4):E63.
44. Influenza symptoms and laboratory diagnostic procedures 2010, Centers for Disease Control and Prevention, Available at:, Accessed September 30, 2011. http://www.cdc.gov/flu/professionals/diagnosis/labprocedures.htm.
45. Centers for Disease Control and Prevention Antiviral agents for the treatment and chemoprophylaxis of influenza - Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011, 60(No. RR-1):1-28.
46. Simonsen L. The global impact of influenza on morbidity and mortality. Vaccine 1999, 17(Suppl 1):S3.
47. Kallen A.J., Brunkard J., Moore Z., et al. Staphylococcus aureus community-acquired pneumonia during the 2006 to 2007 influenza season. Ann Emerg Med 2009, 53(3):358-365.
48. Cox N.J., Subbarao K. Influenza. Lancet 1999, 354(9186):1277-1282.
49. Mamas M.A., Fraser D., Neyses L. Cardiovascular manifestations associated with influenza virus infection. Int J Cardiol 2008, 130(3):304-309.
50. British Infection Society, British Thoracic Society, Health Protection Agency Pandemic flu: clinical management of patients with an influenza-like illness during an influenza pandemic. Provisional guidelines from the British Infection Society, British Thoracic Society, and Health Protection Agency in collaboration with the Department of Health. Thorax 2007, 62(Suppl 1):1-46.
51. Influenza diagnostic testing algorithm 2010, Centers for Disease Control and Prevention, Available at:, Accessed September 30, 2011. http://www.cdc.gov/flu/professionals/diagnosis/testing_algorithm.htm.
52. Oliveira E.C., Lee B., Colice G.L. Influenza in the intensive care unit. J Intensive Care Med 2003, 18(2):80-91.
53. Stein J., Louie J., Flanders S., et al. Performance characteristics of clinical diagnosis, a clinical decision rule, and a rapid influenza test in the detection of influenza infection in a community sample of adults. Ann Emerg Med 2005, 46(5):412-419.
54. Harper S.A., Bradley J.S., Englund J.A., et al. Seasonal influenza in adults and children - diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009, 48(8):1003-1032.
55. Centers for Disease Control and Prevention. Role of laboratory diagnosis of influenza. Available at: Accessed September 30, 2011. http://www.cdc.gov/flu/professionals/diagnosis/labrole.htm.
56. Smit M., Beynon K.A., Murdoch D.R., et al. Comparison of the NOW Influenza A & B, NOW Flu A, NOW Flu B, and Directigen Flu A & B assays, and immunofluorescence with viral culture for the detection of influenza A and B viruses. Diagn Microbiol Infect Dis 2007, 57(1):67-70.
57. Centers for Disease Control and Prevention. Influenza Symptoms and laboratory diagnostic procedures. Available at: Accessed September 30, 2011. http://www.cdc.gov/flu/professionals/diagnosis/labprocedures.htm.
58. Landry M.L. Diagnostic tests for influenza infection. Curr Opin Pediatr 2011, 23(1):91-97.
59. Centers for Disease Control and Prevention. Guidance for clinicians on the use of rapid influenza diagnostic tests for the 2010-2011 influenza season. Available at: Accessed September 30, 2011. http://www.cdc.gov/flu/professionals/diagnosis/clinician_guidance_ridt.htm.
60. WHO recommendations on the use of rapid testing for influenza diagnosis 2005, World Health Organization, Available at:, Accessed September 30, 2011. http://www.who.int/influenza/resources/documents/rapid_testing/en/index.html.
61. Bonner A.B., Monroe K.W., Talley L.I., et al. Impact of the rapid diagnosis of influenza on physician decision-making and patient management in the pediatric emergency department: results of a randomized, prospective, controlled trial. Pediatrics 2003, 112(2):363-367.
62. Hurt A.C., Alexander R., Hibbert J., et al. Performance of six influenza rapid tests in detecting human influenza in clinical specimens. J Clin Virol 2007, 39(2):132-135.
63. Raphael D. Clinical manifestations of seasonal influenza in adults 2010, UpToDate, Available at:, Accessed September 30, 2011. http://www.uptodate.com/contents/clinical-manifestations-of-seasonal-influenza-in-adults?view.
64. Petric M., Comanor L., Petti C.A. Role of the laboratory in diagnosis of influenza during seasonal epidemics and potential pandemics. J Infect Dis 2006, 194(Suppl 2):S98-S110.
65. Centers for Disease Control and Prevention. Rapid Diagnostic testing for influenza. Available at: Accessed September 30, 2011. http://www.cdc.gov/flu/professionals/diagnosis/rapidclin.htm.
66. Cox N.J., Zeigler T. Influenza viruses. Manual of clinical microbiology 2003, 1360-1367. American Society for Microbiology Press, Washington, DC. 8th edition. P.R. Murray, E.J. Benson, H. Jorgemson (Eds.).
67. CDC protocol of realtime RTPCR for influenza A (H1N1) 2009, World Health Organization, Available at:, Accessed September 30, 2011. http://www.who.int/csr/resources/publications/swineflu/CDCRealtimeRTPCR_SwineH1Assay-2009_20090430.pdf.
68. van Elden L.J.R., van Kraaij M.G.J., Nijhuis M., et al. Polymerase chain reaction is more sensitive than viral culture and antigen testing for the detection of respiratory viruses in adults with haematological cancer and pneumonia. Clin Infect Dis 2002, 34(2):177-183.
69. Pollock N.R., Duong S., Cheng A., et al. Ruling out novel H1N1 influenza virus infection with direct fluorescent antigen testing. Clin Infect Dis 2009, 49:66-68.
70. Ginocchio C.C., Zhang F., Manji R., et al. Evaluation of multiple test methods for the detection of the novel 2009 influenza A (H1N1) during the New York City outbreak. J Clin Virol 2009, 45(3):191-195.
71. Centers for Disease Control and Prevention. FluView: 2009-2010 influenza season week 20 ending May 22, 2010. Available at: Accessed September 30, 2011. http://www.cdc.gov/flu/weekly/weeklyarchives2009-2010/weekly20.htm.
72. Aoki F.Y., Macleod M.D., Paggiaro P., et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003, 51(1):123-129.
73. Hayden F.G., Osterhaus A.D., Treanor J.J., et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. GG167 Influenza Study Group. N Engl J Med 1997, 337(13):874-880.
74. Monto A.S., Fleming D.M., Henry D., et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999, 180(2):254-261.
75. Nicholson K.G., Aoki F.Y., Osterhaus A.D., et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000, 355(9218):1845-1850.
76. Hedrick J.A., Barzilai A., Behre U., et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J 2000, 19(5):410-417.
77. Lalezari J., Campion K., Keene O., et al. Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch Intern Med 2001, 161(2):212-217.
78. Monto A.S., Webster A., Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J Antimicrob Chemother 1999, 44(Suppl 2):23-29.
79. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Randomized trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998, 352(9144):1877-1881.
80. Piedra P.A., Schulman K.L., Blumentals W.A. Effects of oseltamivir on influenza-related complications in children with chronic medical conditions. Pediatrics 2009, 124(1):170-178.
81. Siston A.M., Rasmussen S.A., Honein M.A., et al. Pandemic 2009 influenza A (H1N1) virus illness among pregnant women in the United States. JAMA 2010, 303(15):1517-1525.
82. McGeer A., Green K.A., Plevneshi A., et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007, 45(12):1568-1575.
83. Lee N., Cockram C.S., Chan P.K.S., et al. Antiviral treatment for patients hospitalized with severe influenza infection may affect clinical outcomes. Clin Infect Dis 2008, 46(8):1323-1324.
84. Public Health Agency of Canada National Advisory Committee on Immunization Statement on Seasonal Trivalent Inactivated Influenza vaccine (TIV) for 2010-2011. An Advisory Committee Statement (ACS). Canadian Communicable Disease Report 2010, 36:ACS-6.
85. Siegel JD, Rhinehart E, Jackson M, et al, and the Healthcare Infection Control Practices Advisory Committee. 2007 Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings. Available at: Accessed September 30, 2011. http://www.cdc.gov/hicpac/pdf/isolation/Isolation2007.pdf.
86. Public Health Agency of Canada. Guidance: infection prevention and control measures for healthcare workers in acute care and long-term care settings - seasonal influenza. Available at: Accessed September 30, 2011. http://www.phac-aspc.gc.ca/nois-sinp/guide/ac-sa-eng.php.
87. Epidemic- and pandemic-prone acute respiratory diseases: infection prevention and control in health care. Epidemic and pandemic alert and response 2008, World Health Organization, Available at:, Accessed September 30, 2011. http://www.who.int/csr/resources/publications/EPR_AM3_E3.pdf.
88. United States Department of Labor, Occupational Safety and Health Administration (OSHA). Respiratory Protection 1910.134. Personal protective equipment. Available at: Accessed September 30, 2011. http://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=STANDARDS&p_id=12716.
89. Centers for Disease Control and Prevention. Guidelines and recommendations prevention strategies for seasonal influenza in healthcare settings. Available at: Accessed September 30, 2011. http://www.cdc.gov/flu/professionals/infectioncontrol/healthcaresettings.htm.
90. The Ontario health plan for an influenza pandemic in brief 2009, Ontario Ministry of Health and Long-Term Care, Available at:, Accessed September 30, 2011. http://www.health.gov.on.ca/english/providers/program/emu/pan_flu/ohpip2/brief_08.pdf.
91. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009, 360(25):2605-2615.
92. Belshe R.B. Implications of the emergence of a novel H1 influenza virus. N Engl J Med 2009, 360(25):2667-2668.
93. Fisman D.N., Savage R., Gubbay J., et al. Older age and a reduced likelihood of 2009 H1N1 virus infection. N Engl J Med 2009, 361(20):2000-2001.
94. Ontario Ministry of Health and Long-Term Care. What you should know about a flu pandemic. What is the difference between the ordinary/seasonal influenza - or " flu" - and an influenza pandemic? Available at: Accessed September 30, 2011. http://www.health.gov.on.ca/en/public/programs/emu/pan_flu/%234.
95. Early detection of severe emerging or re-emerging respiratory infections through severe respiratory illness (SRI) surveillance 2006, Public Health Agency of Canada, Available at:, Accessed September 30, 2011. http://www.phac-aspc.gc.ca/eri-ire/pdf/02-SRI-Surveillance-Protocol_e.pdf.